emflaza

PTC Shares Additional Update on the Availability of EMFLAZA During COVID-19

PTC has provided additional details about Emflaza during the COVID-19 pandemic. Read PTC Therapeutic’s Statement PTC Therapeutics, Inc. Update on the Availability of EMFLAZA March 27, 2020 We want to assure patients and health care…

Learn More

PTC Shares Update on EMFLAZA Availability During Coronavirus

PTC Therapeutics has shared a statement on EMFLAZA availability during the coronavirus (COVID-19) crisis, stating that the supply of EMFLAZA will not be affected by the coronavirus (COVID-19). PTC reports that they are closely monitoring…

Learn More

August 16, 2019

ICER Releases Report; PPMD Issues Open Letter to Payers

Last night, the Institute for Clinical and Economic Review (ICER) released their final report assessing three Duchenne products: Emflaza, EXONDYS 51, and golodirsen. This report integrates all public comments, stakeholder engagement, and the Roundtable proceedings…

Learn More

PTC Therapeutics Update on Specialty Pharmacy Transition

PTC Therapeutics has shared an update regarding the transitioning of patients that are taking EMFLAZA® (deflazacort) to a new specialty pharmacy, Accredo. Read the Update from PTC: PTC Therapeutics Update on Specialty Pharmacy Transition In…

Learn More

PTC Receives FDA Approval for Expansion of EMFLAZA® (deflazacort) Labeling to Include Patients 2-5 Years of Age

PTC Therapeutics announced that they have received FDA approval for the expansion of the EMFLAZA® (deflazacort) labeling to include patients 2-5 years of age. Emflaza was first approved by the FDA in February 2017 for…

Learn More

February 19, 2019

End Duchenne Tour Recap: Las Vegas, NV

PPMD was thrilled to head to Las Vegas, NV for our first End Duchenne Tour stop of 2019 on February 2. More than 45 people came together to learn about the latest information and resources for Duchenne…

Learn More

October 31, 2018

WATCH: An Update on Corticosteroids – Webinar Recording

PPMD and Dr. John Brandsema hosted a webinar on October 24, 2018 to discuss the current guidelines for steroid use in Duchenne muscular dystrophy, emerging data, and best practices. If you missed the live event,…

Learn More

Join Our Mailing List